newsfilter
← Earnings
Earnings Releases·

Cue Biopharma — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Third quarter 2026 revenue was $0.1 million, a decrease from $2.1 million in the third quarter of 2025, driven by reduced revenue recognition under the BI Collaboration and License Agreement.
    • Research and development expenses were $17.0 million for the quarter ended September 30, 2026, compared to $4.8 million in the same period in 2025, primarily due to increased clinical trial costs and non-cash stock-based compensation.
    • General and administrative expenses were $29.8 million for the quarter ended September 30, 2026, compared to $4.9 million in the same period in 2025, primarily attributed to non-cash stock-based compensation.
    • Net loss for the three months ended September 30, 2026, was $50.0 million, compared to a net loss of $7.4 million in the third quarter of 2025.
    • As of September 30, 2026, the company held $57.9 million in cash and cash equivalents.
    • Other income and expense included a net non-cash loss related to the revaluation of a top-up share obligation to Ascendant.
  • Business Segments and Product Lines:

    • CUE-221: Positive Phase 2 top-line results for chronic spontaneous urticaria (CSU) demonstrated highly statistically significant dose-responsive clinical impact on complete hives resolution (HSS7=0) and complete response (UAS7=0).
    • CUE-221: In the 4 mg/kg dose group, durable clinical benefit persisted at week 28 (12 weeks post-last dose) without clinically meaningful drug exposure, a result not observed at lower doses and significantly greater than XOLAIR® in post-hoc analysis.
    • CUE-221: In a prespecified subgroup of patients with high baseline IgE (≥300 IU/mL), 78% of those receiving 4 mg/kg achieved complete hive resolution at week 12 versus 0% with placebo (P < 0.005).
    • CUE-221: The study enrolled patients with a median baseline IgE of 427 ng/mL, with approximately one-third having high IgE ≥720 ng/mL; 26% of the overall population achieved free IgE levels below the limit of quantification at week 1.
    • CUE-221: The Investigational New Drug (IND) application for food allergy has been cleared by the FDA.
    • CUE-401: Initiated first-in-human Phase 1 dosing, marking the entry of the company's first autoimmune therapeutic candidate into clinical development.
    • CUE-401: Designed as a potentially first-in-class dual-agonist to regulate inflammation and drive Treg-mediated tolerance.
  • Other Key Points:

    • Pursuant to a Second Amendment to the License Agreement with ImmunoScape in November 2026, the right to receive a $5.0 million payment was increased to $5.5 million, payable as $3.0 million in Q4 2026, $1.5 million in Q3 2027, and $1.0 million in Q4 2027.
    • The company reported a significant increase in weighted average common shares outstanding to 10,561,814 for the quarter ended September 30, 2026, compared to 3,362,311 in the same period in 2025.
    • Non-cash stock-based compensation expense related to long-term, performance-based, company-wide incentive equity grants made following a strategic transformation in Q2 2026 significantly impacted operating expenses.
    • Management highlighted that CUE-221's bioavailability is approximately 50% subcutaneous compared to intravenous, enabling evaluation of higher exposures to optimize efficacy.
Company
CUE BIOPHARMA INC
Sector
Healthcare
Industry
Biotechnology